STOCK TITAN

SS Innovations International (SSII) 424B Filings

SSII NASDAQ

Here are the 424B prospectus supplements from SS Innovations International Inc. (SSII) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow SSII and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SSII filings page.

Rhea-AI Summary

SS Innovations International, Inc. is offering Growth Capital Partners, LLC a secured convertible promissory note with $21,025,000 original principal for a $20,000,000 purchase price; estimated net proceeds are approximately $19.9 million. The $1,025,000 difference comprises a $1,000,000 original issue discount and $25,000 of investor transaction expenses. Proceeds are intended for working capital and general corporate purposes, including global marketing, clinical trials and manufacturing capacity.

The note bears 8.75% annual interest, compounded daily, and matures 36 months after the purchase price is delivered. Beginning on the supplement date, the investor may convert at 95% of the lower of the prior trading day's VWAP and the preceding five-trading-day average VWAP, if the trading price exceeds Market Price by at least 10%. Each Limited Redemption has a daily limit equal to the greater of $50,000 and 10% of cumulative daily dollar trading volume. Starting 12 months after the Purchase Price Date, the investor may redeem amounts subject to a monthly limit; payment may be in cash, shares or both at the company's discretion. Collateral includes company and SS IP assets but excludes SSI-India assets and shares; subsidiaries other than SSI-India guarantee the note. The company states conversions may cause substantial dilution and that its losses raise substantial doubt about its ability to continue as a going concern.

Rhea-AI Summary

SS Innovations International, Inc. is offering up to $50,000,000 of common stock in an at-the-market (ATM) program under a Sales Agreement with Virtu Americas LLC dated June 18, 2026.

Sales may occur from time to time on Nasdaq or other U.S. trading venues at market prices; Virtu may act as agent or principal and is entitled to a commission of up to 3.0% of gross proceeds. The number of shares outstanding used for this offering calculation was 200,131,535 shares as of June 17, 2026. Net proceeds, if any, are intended for working capital and general corporate purposes, including global marketing, clinical trials and manufacturing capacity expansion.

Rhea-AI Summary

SS Innovations International, Inc. files a shelf prospectus to register up to $150,000,000 of securities and to permit resale of up to 5,016,500 shares of common stock by selling shareholders.

The prospectus registers multiple securities types (common stock, preferred, warrants, rights, units, debt) and specifically covers 5,016,500 Shares comprised of shares sold in a March 6, 2026 private placement, and shares issuable upon exercise of RCP Warrants (41,667 shares, $3.45 exercise) and HCW Warrants (500,000 shares, $8.89 exercise). The company will receive proceeds only if those warrants are exercised.

The filing describes the SSi Mantra surgical robotic system, regulatory filings including a 510(k) submission to the FDA, an installed base of 194 systems as of March 31, 2026, and cumulative use in 9,744 procedures. The prospectus discloses concentrated control by Dr. Sudhir Srivastava (approx. 55.84% beneficial ownership) and material risk factors including continued losses, regulatory and manufacturing risks, and the need for additional financing.